AI assistant
Edesa Biotech, Inc. — Director's Dealing 2020
Jan 13, 2020
35006_dirs_2020-01-13_1fad1256-7483-4df7-9857-b340bc1c04b0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: Edesa Biotech, Inc. (EDSA)
CIK: 0001540159
Period of Report: 2020-01-08
Reporting Person: Sistilli Carlo (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-01-08 | Common Shares | A | 2436 | $4.11 | Acquired | 2436 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-01-08 | Common Share Warrants (Right to Buy) | $4.8 | A | 1827 | Acquired | 2023-07-08 | Common Shares (1827) | Indirect |
| 2020-01-08 | Common Share Warrants (Right to Buy) | $4.00 | A | 1218 | Acquired | 2020-11-08 | Common Shares (1218) | Indirect |
Footnotes
F1: The reported securities are included within 2,436 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share.
F2: York-Cav Enterprises, Inc. is partially owned by the reporting party.Mr. Sistilli disclaims beneficial ownership except to the extent of his precautionary interest therein.
F3: Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023.
F4: Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020.
F5: Amended to reflect acquisition from the issuer.